QualityStocksNewsBreaks – Branded Legacy, Inc. (OTC: BLEG) Signs LOI to Acquire Bio-Legacy Evaluative Group and Expand Intranasal Drug Delivery Portfolio
Branded Legacy (OTC: BLEG), a diversified holdings company focused on health and wellness solutions, announced the execution of a non-binding Letter of Intent to acquire Bio-Legacy Evaluative Group, a pioneer in advanced intranasal drug delivery technologies. The proposed $1.5 million Preferred D stock transaction would transfer 100% of Bio-Legacy’s equity, assets, and IP, supporting Branded Legacy’s entry into high-growth markets for addiction treatments and vaccine accessibility. Bio-Legacy’s patented naloxone device addresses cost and dosing challenges in a market projected to exceed $1.16 billion by 2032. Following the closing, Bio-Legacy CEO Amin Janmohamed will assume the roles of CEO and Chairman of…